HRP20171580T1 - Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba - Google Patents
Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba Download PDFInfo
- Publication number
- HRP20171580T1 HRP20171580T1 HRP20171580TT HRP20171580T HRP20171580T1 HR P20171580 T1 HRP20171580 T1 HR P20171580T1 HR P20171580T T HRP20171580T T HR P20171580TT HR P20171580 T HRP20171580 T HR P20171580T HR P20171580 T1 HRP20171580 T1 HR P20171580T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- fragment
- amino acid
- fragment according
- constant domain
- Prior art date
Links
- 241000725619 Dengue virus Species 0.000 title claims 3
- 108090000623 proteins and genes Proteins 0.000 title claims 2
- 102000004169 proteins and genes Human genes 0.000 title claims 2
- 239000012634 fragment Substances 0.000 claims 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 206010012310 Dengue fever Diseases 0.000 claims 4
- 101710204837 Envelope small membrane protein Proteins 0.000 claims 4
- 208000025729 dengue disease Diseases 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 101710145006 Lysis protein Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 1
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 1
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 1
- 101710088839 Replication initiation protein Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (24)
1. Izolirano protutijelo ili njegov fragment koji se specifično veže za protein (E) omotača Denga virusa serotipa 1 ili njegov fragment, naznačeno time da je protutijelo ljudsko protutijelo s neutralizirajućom aktivnošću koje se veže preko dva proteina E u virusu, pri čemu vezivanje preko dva proteina E obuhvaća vezanje za DI i zglob između DI i II na jednom proteinu E i DIII na susjednom proteinu E.
2. Protutijelo ili njegov fragment prema zahtjevu 1, naznačeno time da se protutijelo ili njegov fragment bira iz skupine koja se sastoji od: (a) cijele molekule imunoglobulina; (b) scFv; (c) Fab fragmenta; (d) F(ab’)2; i (e) disulfidom povezanog Fv.
3. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
teški lanac konstantne domene imunoglobulina koji se bira iz skupine koju čine: (a) konstantna domena ljudskog IgM; (b) konstantna domena ljudskog IgG1; (c) konstantna domena ljudskog IgG2; (d) konstantna domena ljudskog IgG3; (e) konstantna domena ljudskog IgG4; i (f) konstantna domena ljudskog IgA1/2;
4. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
teški lanac koji se sastoji iz najmanje jednog CDR koji se bira iz skupine CDR-a sa sekvencama aminokiselina SYGMH, VIWYDGSKTYYGDSVKG ili GIAGGWAFW.
5. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
teški lanac koji sadrži tri CDR-a sa sekvencama aminokiselina SYGMH, VIWYDGSKTYYGDSVKG i GIAGGWAFW.
6. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
teški lanac sa sekvencom aminokiselina
[image]
[image]
7. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
okvir teškog lanca IGHV1-2*02 i najmanje jedan CDR sa sekvencom aminokiselina SYGMH, VIWYDGSKTYYGDSVKG ili GIAGGWAFW.;
8. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
laki lanac konstantne domene imunoglobulina koji se bira iz skupine koju čine: (a) ljudska Ig kapa konstantna domena; i (b) ljudska Ig lambda konstantna domena.;
9. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
laki lanac koji sadrži najmanje jedan CDR koji se bira iz skupine CDR-a sa sekvencama aminokiselina RASQNVYSYLG, GVTSRAT ili QQYAG.;
10. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
laki lanac koji sadrži tri CDR-a sa sekvencama aminokiselina RASQNVYSYLG, GVTSRAT i QQYAG.;
11. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
laki lanac sa sekvencom aminokiselina
[image]
ili
[image] ;
12. Protutijelo ili njegov fragment prema zahtjevu 1 ili 2, naznačeno time da protutijelo ili njegov fragment sadrže:
okvir lakog lanca IGKV3-20*01 i najmanje jedan od CDR-a sa sekvencama amino kiselina RASQNVYSYLG, GVTSRAT ili QQYAG.
13. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-12, naznačeno time da je protutijelo:
koje se veže za Denga virus sa specifičnošću vezanja protutijela sa sekvencom aminokiselina teškog lanca EVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKG LEWVAVIWYDGSKTYYGDSVKGRFTISKDNSKKMVNLQMDSLGV EDTAFYYCARGIAGGWAFWGIDLWGQGTLVTVSS i sekvencom aminokiselina lakog lanca
[image]
ili
[image]
14. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-12, naznačeno time da protutijelo:
je protutijelo sa sekvencom aminokiselina teškog lanca
EVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVAVIWYDGSKTYYGDSVKGRFTISKDNSKKMVNLQMDSLGV EDTAFYYCARGIAGGWAFWGIDLWGQGTLVTVSS
i sekvencom aminokiselina lakog lanca
[image]
[image]
ili
[image]
15. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-14, naznačeno time da se protutijelo ili njegov fragment vežu za antigen s konstantom afiniteta (KD) koja je manja od 1 x 10-8 M, i proizvoljno vežu za antigen s konstantom afiniteta (KD) koja je manja od 1 x 10-9 M.
16. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-15, naznačeno time da je protutijelo porijeklom od B stanica pacijenta koji se oporavio od infekcije Denga virusom.
17. Farmaceutski pripravak naznačen time da sadrži protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-16 i farmaceutski prihvatljiv nosač koji je učinkovit za smanjenje ili prevenciju infekcije Denga virusom kod subjekta.
18. Farmaceutski pripravak prema zahtjevu 17, naznačen time da nadalje sadrži drugo sredstvo.
19. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-16 naznačeno time da je za upotrebu u postupku pasivne imunizacije protiv infekcije Denga virusom koji obuhvaća davanje subjektu učinkovite količine protutijela ili njegovog fragmenta prema bilo kojem od zahtjeva 1-16.
20. Protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-16 naznačeno time da je za upotrebu u postupku liječenja infekcije Denga virusom koji obuhvaća davanje subjektu kojem je potrebno količine protutijela ili njegovog fragmenta prema bilo kojem od zahtjeva 1-16 koja je učinkovita da se bolest ublaži ili spriječi.
21. Protutijelo za upotrebu prema zahtjevu 20, naznačeno time da:
se protutijelo daje intravenozno (IV), supkutano (SC), intramuskularno (IM), transdermalno, ili oralno; ili se protutijelo daje u količini koja je u rasponu od 1 do 100 miligrama po kilogramu tjelesna mase subjekta; ili navedena upotreba nadalje sadrži davanje drugog sredstva, proizvoljno kada je drugo sredstvo antivirusni lijek ili analgetički lijek.
22. Izolirana nukleinska kiselina naznačena time da kodira protutijelo ili njegov fragment prema bilo kojem od zahtjeva 1-16.
23. Ekspresijski vektor naznačen time da sadrži nukleinsku kiselinu prema zahtjevu 22.
24. Stanica domaćin naznačena time da sadrži ekspresijski vektor 23, proizvoljno kada je stanica domaćin bakterijska stanica, eukariotska stanica, ili stanica sisavca.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42308510P | 2010-12-14 | 2010-12-14 | |
| PCT/SG2011/000436 WO2012082073A1 (en) | 2010-12-14 | 2011-12-14 | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
| EP11848839.4A EP2651975B1 (en) | 2010-12-14 | 2011-12-14 | Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171580T1 true HRP20171580T1 (hr) | 2018-01-26 |
Family
ID=46244986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171580TT HRP20171580T1 (hr) | 2010-12-14 | 2017-10-17 | Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9376486B2 (hr) |
| EP (1) | EP2651975B1 (hr) |
| JP (2) | JP6483337B2 (hr) |
| KR (2) | KR101781546B1 (hr) |
| CN (1) | CN103534270B (hr) |
| AU (2) | AU2011341744B2 (hr) |
| BR (1) | BR112013015129B1 (hr) |
| CA (1) | CA2821268C (hr) |
| CO (1) | CO6801636A2 (hr) |
| CY (1) | CY1119854T1 (hr) |
| DK (1) | DK2651975T3 (hr) |
| EA (1) | EA201390874A1 (hr) |
| ES (1) | ES2644236T3 (hr) |
| HR (1) | HRP20171580T1 (hr) |
| HU (1) | HUE035609T2 (hr) |
| IL (1) | IL226957B (hr) |
| LT (1) | LT2651975T (hr) |
| MX (1) | MX348152B (hr) |
| MY (1) | MY166537A (hr) |
| PH (1) | PH12017501075A1 (hr) |
| PL (1) | PL2651975T3 (hr) |
| PT (1) | PT2651975T (hr) |
| RS (1) | RS56737B1 (hr) |
| SG (2) | SG191155A1 (hr) |
| SI (1) | SI2651975T1 (hr) |
| WO (1) | WO2012082073A1 (hr) |
| ZA (1) | ZA201304459B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102225009B1 (ko) | 2007-09-26 | 2021-03-08 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| EA201390874A1 (ru) * | 2010-12-14 | 2013-12-30 | Нэшнл Юниверсити Оф Сингапур | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение |
| US9821050B2 (en) | 2012-04-02 | 2017-11-21 | The University Of North Carolina At Chapel Hill | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions |
| WO2014064707A1 (en) * | 2012-10-26 | 2014-05-01 | International Centre For Genetic Engineering And Biotechnology | Pichia pastoris -expressed dengue virus like particles |
| US10053493B2 (en) | 2013-06-26 | 2018-08-21 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus vaccines |
| KR102356951B1 (ko) | 2014-02-11 | 2022-01-27 | 비스테라, 인크. | 뎅기열 바이러스에 대한 항체 분자 및 그의 용도 |
| MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
| TWI763660B (zh) | 2016-03-25 | 2022-05-11 | 美商威特拉公司 | 登革病毒的抗體分子之配方設計 |
| US11053308B2 (en) | 2016-08-05 | 2021-07-06 | Chugai Seiyaku Kabushiki Kaisha | Method for treating IL-8-related diseases |
| SG10201607778XA (en) * | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
| CN112119090B (zh) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | 对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法 |
| US10526398B2 (en) * | 2018-06-12 | 2020-01-07 | National Defense Medical Center | Anti-dengue virus antibodies and applications thereof |
| US20210188948A1 (en) * | 2018-08-07 | 2021-06-24 | Chan Zuckerberg Biohub, Inc. | Antibodies against dengue virus and related methods |
| WO2021102363A1 (en) * | 2019-11-20 | 2021-05-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development |
| WO2022162009A1 (en) | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
| WO2022161597A1 (en) * | 2021-01-26 | 2022-08-04 | Eth Zurich | Method for rapid identification of cross-reactive and/or rare antibodies |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| DE3223885A1 (de) | 1982-06-26 | 1983-12-29 | Basf Ag, 6700 Ludwigshafen | Makroporoese, hydrophile traeger fuer enzyme |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5651991A (en) | 1987-10-28 | 1997-07-29 | Nippon Shinyaku Co. Ltd. | Drug carriers |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| KR940003548U (ko) | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
| WO1994019376A1 (en) | 1993-02-26 | 1994-09-01 | Drug Delivery System Institute, Ltd. | Polysaccharide derivative and drug carrier |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| JPH08510761A (ja) | 1994-03-07 | 1996-11-12 | ザ・ダウ・ケミカル・カンパニー | 生物活性及び／又はターゲテッドデンドリマー複合体 |
| JP3631755B2 (ja) | 1994-03-23 | 2005-03-23 | 明治製菓株式会社 | ポリオキシエチレン含有脂質二本鎖誘導体 |
| JP3699141B2 (ja) | 1994-09-24 | 2005-09-28 | 伸彦 由井 | 超分子構造の生体内分解性医薬高分子集合体及びその調製方法 |
| US5490840A (en) | 1994-09-26 | 1996-02-13 | General Electric Company | Targeted thermal release of drug-polymer conjugates |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US6106866A (en) | 1995-07-31 | 2000-08-22 | Access Pharmaceuticals, Inc. | In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| KR100856446B1 (ko) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ｃｔｌａ－４에 대한 인간 단일클론 항체 |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
| CA2894300A1 (en) * | 2003-12-08 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secreatary, Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
| US7981431B2 (en) | 2007-06-08 | 2011-07-19 | National Health Research Institutes | Consensus dengue virus envelope protein domain III polypeptides (cED III) and their methods of use |
| GB0724065D0 (en) | 2007-12-10 | 2008-01-16 | Sparrow Paul A | A spirit level |
| US20110150914A1 (en) | 2008-06-09 | 2011-06-23 | La Jolla Institute For Allergy And Immunology | Compositions and methods for dengue virus (dv) treatment and vaccination |
| WO2010043977A2 (en) | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| WO2010093335A1 (en) | 2009-02-10 | 2010-08-19 | Nanyang Technological University | Antibodies for diagnosis and treatment of flaviviral infections |
| EA201390874A1 (ru) | 2010-12-14 | 2013-12-30 | Нэшнл Юниверсити Оф Сингапур | Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение |
-
2011
- 2011-12-14 EA EA201390874A patent/EA201390874A1/ru unknown
- 2011-12-14 MY MYPI2013002206A patent/MY166537A/en unknown
- 2011-12-14 SG SG2013045745A patent/SG191155A1/en unknown
- 2011-12-14 LT LTEP11848839.4T patent/LT2651975T/lt unknown
- 2011-12-14 EP EP11848839.4A patent/EP2651975B1/en active Active
- 2011-12-14 BR BR112013015129-3A patent/BR112013015129B1/pt active IP Right Grant
- 2011-12-14 AU AU2011341744A patent/AU2011341744B2/en active Active
- 2011-12-14 ES ES11848839.4T patent/ES2644236T3/es active Active
- 2011-12-14 SG SG10201510111PA patent/SG10201510111PA/en unknown
- 2011-12-14 CA CA2821268A patent/CA2821268C/en active Active
- 2011-12-14 MX MX2013006710A patent/MX348152B/es active IP Right Grant
- 2011-12-14 KR KR1020137018382A patent/KR101781546B1/ko active IP Right Grant
- 2011-12-14 RS RS20171031A patent/RS56737B1/sr unknown
- 2011-12-14 SI SI201131313T patent/SI2651975T1/en unknown
- 2011-12-14 HU HUE11848839A patent/HUE035609T2/hu unknown
- 2011-12-14 KR KR1020177026209A patent/KR101904232B1/ko active IP Right Grant
- 2011-12-14 JP JP2013544435A patent/JP6483337B2/ja active Active
- 2011-12-14 CN CN201180066887.9A patent/CN103534270B/zh active Active
- 2011-12-14 US US13/993,983 patent/US9376486B2/en active Active
- 2011-12-14 WO PCT/SG2011/000436 patent/WO2012082073A1/en active Application Filing
- 2011-12-14 PL PL11848839T patent/PL2651975T3/pl unknown
- 2011-12-14 PT PT118488394T patent/PT2651975T/pt unknown
- 2011-12-14 DK DK11848839.4T patent/DK2651975T3/en active
-
2013
- 2013-06-13 IL IL226957A patent/IL226957B/en active IP Right Grant
- 2013-06-18 ZA ZA201304459A patent/ZA201304459B/en unknown
- 2013-07-12 CO CO13165679A patent/CO6801636A2/es active IP Right Grant
-
2016
- 2016-06-01 US US15/170,838 patent/US10294293B2/en active Active
- 2016-12-08 AU AU2016269515A patent/AU2016269515A1/en not_active Abandoned
-
2017
- 2017-06-08 PH PH12017501075A patent/PH12017501075A1/en unknown
- 2017-10-17 HR HRP20171580TT patent/HRP20171580T1/hr unknown
- 2017-10-20 JP JP2017203328A patent/JP2018046835A/ja not_active Withdrawn
- 2017-11-08 CY CY20171101173T patent/CY1119854T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171580T1 (hr) | Ljudska monoklonska protutijela koja su specifična za protein e denga virusa serotipa 1 i njihova upotreba | |
| HRP20180945T1 (hr) | Konjugati protutijelo-pirolobenzodiazepin | |
| HRP20200887T1 (hr) | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa | |
| TWI689314B (zh) | 低親和力血腦障壁受體抗體及其用途 | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| HRP20171315T1 (hr) | Optimizacija humanih antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene | |
| CN110418803B (zh) | 抗rsv单克隆抗体配制品 | |
| JP2006511516A5 (hr) | ||
| HRP20170342T1 (hr) | Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice | |
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| JP2020002172A5 (hr) | ||
| RU2017145653A (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| JP6453278B2 (ja) | 皮膚科的病理の治療 | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| TW201637667A (zh) | 治療或預防偏頭痛之方法 | |
| JP2008540447A5 (hr) | ||
| JP2009532336A5 (hr) | ||
| RU2014125320A (ru) | Химерное терапевтическое антитело нн1 против cd-37 | |
| CN109963577B (zh) | 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法 | |
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| KR102167261B1 (ko) | 관절염 치료 | |
| JP2020502219A5 (hr) | ||
| TW201406398A (zh) | 醫藥調配物 | |
| JP2018522540A5 (hr) | ||
| WO2020108612A1 (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 |